NCT00002231已完成1 期
GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Dose Escalation Study of GENEVAX-HIV Delivered Intramuscularly Using the Biojector 2000 in HIV Seronegative Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a new HIV vaccine, to HIV-negative volunteers. This study will also look at how this vaccine affects the immune system of these volunteers.
详细描述
In this open-label study, volunteers are given an intramuscular injection of GENEVAX-HIV vaccine using the Biojector 2000. Safety measures and immune response are assessed accordingly.
研究设计
- 研究类型
- Interventional
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study of GENEVAX-HIV, a Possible VaccineHIV SeronegativityHIV InfectionsNCT00002232Wyeth-Lederle Vaccines
已完成
1 期
Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy AdultsHIV InfectionsNCT00301184National Institute of Allergy and Infectious Diseases (NIAID)120
已完成
1 期
Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV InfectionHIV InfectionsNCT00125099National Institute of Allergy and Infectious Diseases (NIAID)21
已完成
1 期
HIV-1 Vaccine Test in Uninfected Adult VolunteersHealthyHIV SeronegativityNCT00009685National Institute of Allergy and Infectious Diseases (NIAID)21
已完成
1 期
Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in UgandaHIV InfectionsNCT00007423National Institute of Allergy and Infectious Diseases (NIAID)40